Generate Biomedicines Stock Forecast
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 13.99 0.00%
GENB analyst consensus
Consensus (6 analysts)
strong_buy
Avg. price target
$27.00+92.99%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 6 Wall Street analysts covering Generate Biomedicines (2026-10-07), 6 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $27.00, with a high estimate of $30.00 and a low estimate of $22.00. The average target implies upside of 93.0% from the current price of $13.99.
The spread between the highest and lowest targets is 36.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for GENB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 33% |
| Buy | 4 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $22.00 | +57.26% |
| Average target | $27.00 | +92.99% |
| High target | $30.00 | +114.44% |